Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01025232 · ClinicalTrials.gov registry record · Phase 1
A Study of Intravitreal Injections of 2.0mg Ranibizumab in Subjects With Chronic Fluid On OCT Post Multiple Injections With Ranibizumab (Super-dose Anti-VEgf SAVE Trial)
A Phase 1 study, sponsored by David M. Brown, M.D..
- Terminated
- Registry status
- Phase 1
- Development phase
- 88
- Enrollment target
NCT01025232: Clinical Trial Phase 1 study, sponsored by David M. Brown, M.D..
NCT01025232 is a Phase 1 study that was terminated before completion, run by David M. Brown, M.D.. The registered enrollment target is 88 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (47% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01025232, a Phase 1 study, was terminated before completion, sponsored by David M. Brown, M.D..
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 88 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether 2.0mg Ranibizumab is effective in the treatment of recurrent fluid.
Primary Outcome
Early Treatment Diabetic Retinopathy Study Best Corrected Visual Acuity (ETDRS BCVA) was used to quantify visual acuity. BCVA is measured using an eye chart and is reported as the number of letters read correctly using the ETDRS Scale (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved.
Interventions
- DRUG Ranibizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2009-12 |
| Est. Completion | 2013-01 |
| Phase | Phase 1 |
Why NCT01025232 stopped before completion
NCT01025232 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 88 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (47% higher).
The record links to 0 conditions, and to 1 intervention - of which Ranibizumab is the first listed.
NCT01025232 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01025232 about?
NCT01025232 is a clinical study titled "A Study of Intravitreal Injections of 2.0mg Ranibizumab in Subjects With Chronic Fluid On OCT Post Multiple Injections With Ranibizumab (Super-dose Anti-VEgf SAVE Trial)". The purpose of this study is to determine whether 2.0mg Ranibizumab is effective in the treatment of recurrent fluid.
What is the current status of trial NCT01025232?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 88 participants. The study started on 2009-12. Estimated completion is 2013-01.
What interventions are being tested in trial NCT01025232?
The interventions under investigation include: Ranibizumab (DRUG).
Who is sponsoring clinical trial NCT01025232?
This trial is sponsored by David M. Brown, M.D., which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01025232's enrollment target sits among peer trials
88 650th of 2000 higher than 1,350 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03843463 · 88 participants · Phase 2
Escitalopram and Language Intervention for Subacute Aphasia
- NCT04066348 · 88 participants · Phase 2
TNF-α Treatment of Blast-Induced Tinnitus
- NCT04331704 · 88 participants · Phase 4
ANCHORS Alcohol & Sexual Health Study: UH3 Project
- NCT04536103 · 88 participants
Multi-Vendor Multi-Site Novel Accelerated MRI Relaxometry
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia